Zentalis Pharmaceuticals
ZNTL
139 hedge funds and large institutions have $3.58B invested in Zentalis Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 53 increasing their positions, 33 reducing their positions, and 14 closing their positions.
623% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $1.51M
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
171% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 14
61% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 33
32% more capital invested
Capital invested by funds: $2.71B → $3.58B (+$865M)
20% more funds holding
Funds holding: 116 → 139 (+23)
3.31% more ownership
Funds ownership: 91.57% → 94.88% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$50.5M |
| 2 |
PA
Perceptive Advisors
New York
|
+$33.3M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$28.5M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$17.1M |
| 5 |
Holocene Advisors
New York
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$38.9M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$28.3M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$23.8M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$11.5M |
| 5 |
Two Sigma Investments
New York
|
-$11.2M |
ZNTL Hedge Fund Activity: Q4 2021 in Review
139 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2021, worth a combined $3.58B — up 32% from $2.71B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ZNTL positions and 14 closed out — a net gain of 24 holders — while 53 added to existing stakes and 33 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $50.5M. The largest seller was Citadel Advisors, cutting an estimated $38.9M.
- 139 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2021, up from 116 in Q3 2021.
- Funds reported $3.58B of Zentalis Pharmaceuticals stock for Q4 2021, up 32% quarter-over-quarter.
- 38 funds opened new Zentalis Pharmaceuticals positions in Q4 2021 and 14 closed out, a net change of +24 holders.
- The largest Zentalis Pharmaceuticals buyer in Q4 2021 was T. Rowe Price Associates, an estimated $50.5M added.
- The largest Zentalis Pharmaceuticals seller in Q4 2021 was Citadel Advisors, an estimated $38.9M sold.
Based on aggregated 13F filings for Q4 2021.